Litcius/Paper detail

DETERMINATION OF PROTEINS SPECIFICATION WITH SARS- COVID-19 BASED LIGAND DESIGNING

Sara Shahriari, Majid Monajjemi, Fatemeh Mollaamin

2022Journal of the Chilean Chemical Society26 citationsDOIOpen Access PDF

Abstract

Towards to recognize a strong inhibitor we accomplished docking studies on the major virus protease with 4 natural product species as anti Covid-19(SARS-CoV-2), namely "Vidarabine", "Cytarabine", "Gemcitabine" and "Matrine" from which are extractive from Gillan's leaves plants. These are known as Chuchaq, Trshvash, Cote-Couto and Khlvash in Iran. Among these four studied compounds, Cytarabine appear as suitable compound with high effectiveness inhibitors to this protease. With docking simulation and NMR investigation we demonstrated, these compounds exhibit a suitable binding energy around 9 Kcal/mol with various ligand proteins modes in the binding to COVID-19 viruses. However, these data need further in both, vivo & vitro evaluation for repurposing these drugs against COVID-19 viruses.

Topics & Concepts

Docking (animal)Coronavirus disease 2019 (COVID-19)ChemistrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)In vitroNatural productProteaseCombinatorial chemistryVirology2019-20 coronavirus outbreakStereochemistryPharmacologyIn vivoComputational biologyBiochemistryEnzymeBiologyMedicineBiotechnologyNursingInfectious disease (medical specialty)OutbreakDiseasePathologyComputational Drug Discovery MethodsDrug-Induced Hepatotoxicity and ProtectionDiverse Scientific Research Studies